VIDAS FT4— 510(k) K132058

Name: FDA 510(k) clearance K132058
Creator: U.S. Food and Drug Administration
Published: 2015-06-08

Substantially Equivalent

Biomerieux S.A.

FDA 510(k) clearance K132058 for VIDAS FT4, Substantially Equivalent on 2015-06-08. Applicant: Biomerieux S.A.. Device class: 2.

Clearance details

Applicant: Biomerieux S.A.
Product code: Code CEC
Device class: Class 2
Regulation: 21 CFR 862.1695
Advisory panel: Clinical Chemistry
Date received: 2013-07-03
Decision date: 2015-06-08
Decision: Substantially Equivalent
Clearance type: Traditional
Location: Craponne, FR

Download summary PDF View on FDA.gov ↗

Recent devices under product code CEC

view all

K240273 — Access Free T42024-03-06
K220456 — Elecsys FT4 IV2023-04-07
K182423 — MAGLUMI 2000 FT42018-10-04
K181233 — Elecsys FT4 III2018-09-18
K173122 — Abbott Architect Free T42017-10-27

More clearances from Biomerieux S.A.

view all

K250274 — ETEST Imipenem/Relebactam P. aeruginosa (IRPA) (0.008/4-128/4 µg/mL)2025-04-30
K210757 — ETEST Fosfomycin (FO) (0.032-512 µg/mL)2021-11-12
K192738 — ETEST Delafloxacin (DFX) (0.002-32 µg/mL)2019-11-26
K192050 — ETEST Eravacycline (ERV) (0.002 32 µg/mL)2019-09-27
K191953 — ETEST Imipenem/Relebactam (IPR) (0.002/4-32/4 ug/mL)2019-08-22

Adverse events under product code CEC

product code CEC

Malfunction: 899
Total: 899

Source: openFDA MAUDE database, 2020-01-01 through 2026-04-23. Counts aggregate all devices under this product code, not just this specific clearance. Reports are submissions to FDA, not validated events. Search MAUDE directly →

Data sourced from openFDA. This site is unofficial and independent of the FDA.